Cramer’s Stock Picks at the Market Top
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Headquartered in Danbury, CT Fiscal year ends December NASDAQ: MNKD mannkindcorp.com
MannKind Corporation is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. It specializes in drug-device combinations.
Its commercial products are:
- Afrezza, an inhaled insulin for adults that recently launched a pediatric indication.
- Furoscix, a subcutaneous furosemide for fluid overload in heart failure and chronic kidney disease, acquired through the October 2025 purchase of scPharma. Its newer ReadyFlow presentation was approved and began shipping in September 2026.
- V-Go, a wearable insulin delivery device.
MannKind also earns substantial revenue from United Therapeutics. This comes through manufacturing and collaboration services and a royalty on net sales of Tyvaso DPI, which is built on MannKind's Technosphere dry-powder inhalation platform.
Its development pipeline includes:
- Nintedanib DPI (MNKD-201) for idiopathic pulmonary fibrosis, now entering a global Phase 2 trial.
- Ralinepag DPI (MNKD-1501), to be clinically developed by United Therapeutics, with milestone payments expected in 2027.
- An inhaled short-acting GLP-1 for weight management, licensed with Rose Pharma. Updated
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks was mixed.
The April 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The April 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The March 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks shrank.
The March 13 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The February 28 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The January 31 data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The January 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
MannKind Corporation is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. It specializes in drug-device combinations.
The Wall Street consensus 12-month price target for MNKD is $8.33.